TABLE 3.
Children and Adolescents |
Adults |
||||
US Borna, No. (%) | Foreign Bornb, No. (%) | US Bornc, No. (%) | Foreign Bornd, No. (%) | ||
Male | 6 435 (50) | 2 947 (51) | 81 189 (67) | 62 182 (60) | |
Median age, y | 3 | 11 | 50 | 41 | |
Race/ethnicity | |||||
Hispanice | 4 952 (39) | 2 664 (46) | 14 355 (12) | 38 435 (37) | |
Non-Hispanic White | 1 491 (12) | 377 (6) | 45 600 (37) | 6 499 (6) | |
Non-Hispanic Black or African American | 4 865 (38) | 1 211 (21) | 56 195 (46) | 12 324 (12) | |
Non-Hispanic American Indian or Native Alaskan | 300 (2) | 3 (< 1) | 2 751 (2) | 67 (< 1) | |
Non-Hispanic Asian or Pacific Islander | 1 049 (8) | 1 494 (26) | 2 321 (2) | 46 005 (44) | |
Site of disease | |||||
Pulmonary only | 9 074 (71) | 4 178 (72) | 93 457 (77) | 72 621 (70) | |
Extrapulmonary only | 2 746 (21) | 1 337 (23) | 18 881 (16) | 23 251 (22) | |
Both | 1 028 (8) | 291 (5) | 9 413 (8) | 8 150 (8) | |
Sputum culture positivef | 1 526 (42) | 1 397 (45) | 75 960 (79) | 60 706 (73) | |
Other culture positiveg | 2 609 (52) | 859 (48) | 39 217 (82) | 33 519 (81) | |
Drug susceptibility testing doneh | 3 666 (94) | 2 049 (97) | 97 922 (95) | 82 995 (97) | |
Drug resistancei | |||||
None | 3 115 (85) | 1 633 (80) | 88 665 (91) | 68 164 (82) | |
INH resistant | 226 (6) | 242 (12) | 4 948 (5) | 9 294 (11) | |
MDRj | 54 (1) | 48 (2) | 1 023 (1) | 1 503 (2) | |
XDRk | 1 (2) | 1 (2) | 16 (2) | 23 (2) | |
HIV statusl | |||||
No result | 9 730 (76) | 4 037 (70) | 55 728 (46) | 59 939 (58) | |
Positive | 121 (4) | 41 (2) | 16 737 (25) | 5 503 (12) | |
Negative | 2 989 (95) | 1 722 (97) | 49 198 (74) | 38 537 (87) | |
Indeterminate | 13 (< 1) | 6 (< 1) | 135 (< 1) | 66 (< 1) | |
Alive at diagnosis | 12 814 (99.7) | 5 790 (99.7) | 116 357 (96) | 102 427 (98) | |
Outcomem | |||||
Completed treatment | 11 640 (91) | 5 179 (89) | 88 589 (76) | 81 281 (79) | |
Died | 69 (1) | 25 (< 1) | 14 789 (13) | 5 017 (5) | |
Othern | 1 105 (9) | 514 (9) | 12 979 (11) | 16 129 (16) |
Note. INH =isoniazid ; MDR = multidrug resistant; TB = tuberculosis; XDR = extensively drug resistant.
n = 12 853, or 69%.
n = 5806, or 31%.
n = 121 798, or 54%.
n = 104 045, or 46%.
May be of any race or multiple races.
For persons in each group who had sputum culture result: US-born children and adolescents, n = 3644; foreign-born children and adolescents, n = 3128; US-born adults, n = 95 925; foreign-born adults, n = 82 869.
For persons in each group who had other culture result (gastric aspirates and tissues or fluids other than sputum): US-born children and adolescents, n = 5010; foreign-born children and adolescents, n = 1795; US-born adults, n = 47 692; foreign-born adults, n = 41 217.
For persons with a positive culture.
For persons who were tested for drug susceptibility because of initial susceptibility test results.
Resistant to at least isoniazid and rifampin.
Resistant to at least isoniazid and rifampin among first-line anti-TB drugs, resistant to any fluoroquinolone (e.g., ciprofloxacin or ofloxacin), and resistant to at least 1 second-line injectable drug (e.g., amikacin, capreomycin, or kanamycin). Percentage XDR uses MDR TB as denominator.
Positive, negative, and indeterminate figures are for persons who had a known HIV test result; all California data were reported as no result.
For persons alive at diagnosis: US-born and adolescents, n = 12 814, foreign-born and adolescents, n = 5790; US born adults, n = 116 357; foreign-born adults, n = 102 427.
Moved, lost to follow-up, uncooperative or refused, other, unknown, or missing.